Skip to main content

DaVita Value Stock - Dividend - Research Selection

Davita

ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


New Strong Buy Stocks for February 27th

2026-02-27
NABZY, DVA, FOR, RUN and ONTO have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2026.

Best Value Stocks to Buy for February 27th

2026-02-27
PAX, DVA and ACT made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 27, 2026.

Best Growth Stocks to Buy for February 27th

2026-02-27
DVA, ALL, and PAX it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2026.

DaVita’s 20-Year Fortune Streak And What It Signals For Investors

2026-02-27
DaVita (NYSE:DVA) has been named to Fortune's World's Most Admired Companies list for the 20th consecutive year. The company ranked third in its category, with recognition tied to culture, clinical focus, and social responsibility. This milestone reflects long running external recognition of DaVita's employer brand and approach to patient care. For investors watching NYSE:DVA, this recognition arrives with the stock at a share price of $152.54 and multi year returns of 88.4% over 3 years...

DaVita Celebrates 20 Years on Fortune's List of World's Most Admired Companies

2026-02-26
Two decades of recognition underscore leadership in clinical innovation, employer strategy NORTHAMPTON, MA / ACCESS Newswire / February 26, 2026 / DaVita, a leading provider of comprehensive kidney care, has been named to Fortune's World's Most Admired ...

DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

2026-02-24
DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST.

Best Value Stocks to Buy for February 24th

2026-02-24
SSL, DLX and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2026.

AllianceBernstein Global High Income Fund, Inc. Releases Monthly Portfolio Update

2026-02-23
AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of January 31, 2026.

Is DaVita (DVA) Stock Undervalued Right Now?

2026-02-23
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How The DaVita (DVA) Investment Story Is Shifting With New Targets And Fair Value Assumptions

2026-02-23
DaVita’s refreshed fair value estimate has shifted from US$147.75 to US$151.71, reflecting a modest 2.7% adjustment in the modelled price target. That move aligns with a series of price target changes from several firms, where higher targets sit alongside research that still flags meaningful risks for you to weigh. As you read on, you will see how these updates fit into the evolving analyst narrative and what to watch if you are tracking DaVita’s story over time. Stay updated as the Fair...